Company news
-
ImmuneOnco announced completion of $89 million round C fund-raisingOn March 24, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced the completion of a $89 million round C financing. The financing was co-led by the Greater Bay Area Homeland Investments Fund (Greater Bay Area Fund) and Lilly Asia Fund (LAV)......2021-04-22 -
ImmuneOnco received ‘Hi-Tech Enterprise Certificate’On March 05, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter refer to as ImmuneOnco) announced receiving ‘Hi-Tech Enterprise Certificate’. This certificate is jointly issued by Shanghai Municipal Science and Technology Commission, Sh......2021-04-22 -
New indications of IMM01 project of ImmuneOnco obtained NMPA clinical trial research licenseOn January 20, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first Fc fusion protein drug targeting human CD47 (Project No.: IMM01) in China, expanding new indications (MM, AML and MDS) and obtaining NMPA clinical trial researc......2021-01-20 -
IMM0306 project of ImmuneOnco has been approved by FDAOn January 9, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the company's self-developed bispecific antibody drug (Project No.: IMM0306) targeting both CD47 and CD20 has obtained the US FDA clinical trial research license. It was o......2021-01-09 -
The bispecific antibody drugs targeting PD-L1 and VEGF simultaneously obtained NMPA clinical trial research licenseOn December 28, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the company's bispecific antibody drug (Project No.: IMM2510) targeting PD-L1 and VEGF has recently obtained the NMPA clinical trial research license (acceptance No.:CXS......2020-12-28